281 related articles for article (PubMed ID: 27661011)
21. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of autoantibodies (ANA, anti ds-DNA, ENA, IMF) and rheumatic syndromes in patients with lymphoproliferative diseases.
Chloraki-Bobota A; Megalakaki C; Repousis P; Chalkiopoulou I; Lalaki I; Trafalis DT; Athanassiou AE; Mitsouli-Mentzikof C
J BUON; 2006; 11(4):485-9. PubMed ID: 17309182
[TBL] [Abstract][Full Text] [Related]
23. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.
Barouta G; Katsiari CG; Alexiou I; Liaskos C; Varna A; Bogdanos DP; Germenis AE; Sakkas LI
Clin Rheumatol; 2017 Apr; 36(4):885-894. PubMed ID: 27943044
[TBL] [Abstract][Full Text] [Related]
24. Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study.
Nell-Duxneuner V; Machold K; Stamm T; Eberl G; Heinzl H; Hoefler E; Smolen JS; Steiner G
Ann Rheum Dis; 2010 Jan; 69(1):169-74. PubMed ID: 19153104
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis.
Chang PY; Yang CT; Cheng CH; Yu KH
Int J Rheum Dis; 2016 Sep; 19(9):880-6. PubMed ID: 25940989
[TBL] [Abstract][Full Text] [Related]
26. [Antibodies to citrullinated proteins in rheumatoid arthritis].
Matsui T
Nihon Rinsho Meneki Gakkai Kaishi; 2006 Apr; 29(2):49-56. PubMed ID: 16651702
[TBL] [Abstract][Full Text] [Related]
27. High prevalence of antinuclear antibodies in children with thyroid autoimmunity.
Segni M; Pucarelli I; Truglia S; Turriziani I; Serafinelli C; Conti F
J Immunol Res; 2014; 2014():150239. PubMed ID: 24741574
[TBL] [Abstract][Full Text] [Related]
28. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
Greiner A; Plischke H; Kellner H; Gruber R
Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
[TBL] [Abstract][Full Text] [Related]
29. The assessment of rheumatoid factor levels and hemogram parameters as predictors for rheumatologic disease.
Limon M
Int J Rheum Dis; 2023 Jun; 26(6):1041-1047. PubMed ID: 36972926
[TBL] [Abstract][Full Text] [Related]
30. [Anti-cyclic citrullinated peptide antibodies and rheumatoid arthritis].
Hayashi N; Kumagai S
Rinsho Byori; 2010 May; 58(5):466-79. PubMed ID: 20560456
[TBL] [Abstract][Full Text] [Related]
31. Dense fine speckled indirect immunofluorescence pattern in an Australian population.
Broadfoot A; Sivertsen T; Baumgart K
Pathology; 2016 Apr; 48(3):247-50. PubMed ID: 27020500
[TBL] [Abstract][Full Text] [Related]
32. The development of anticyclic citrullinated peptide (anti-CCP) antibody following severe COVID-19.
Roghani SA; Dastbaz M; Lotfi R; Shamsi A; Abdan Z; Rostampour R; Soleymani B; Zamanian MH; Soufivand P; Pournazari M; Taghadosi M
Immun Inflamm Dis; 2024 May; 12(5):e1276. PubMed ID: 38780036
[TBL] [Abstract][Full Text] [Related]
33. Italian multicentre study for application of a diagnostic algorithm in autoantibody testing for autoimmune rheumatic disease: conclusive results.
Bonaguri C; Melegari A; Ballabio A; Parmeggiani M; Russo A; Battistelli L; Aloe R; Trenti T; Lippi G
Autoimmun Rev; 2011 Nov; 11(1):1-5. PubMed ID: 21741498
[TBL] [Abstract][Full Text] [Related]
34. Autoantibodies and the risk of cardiovascular events.
Liang KP; Kremers HM; Crowson CS; Snyder MR; Therneau TM; Roger VL; Gabriel SE
J Rheumatol; 2009 Nov; 36(11):2462-9. PubMed ID: 19833748
[TBL] [Abstract][Full Text] [Related]
35. Association of human leukocyte antigen DRB1 with anti-cyclic citrullinated peptide autoantibodies in Saudi patients with rheumatoid arthritis.
Alrogy A; Dirar A; Alrogy W; Fakhoury H; Hajeer A
Ann Saudi Med; 2017; 37(1):38-41. PubMed ID: 28151455
[TBL] [Abstract][Full Text] [Related]
36. [Comparison and relevance of rheumatoid factors, antikeratin antibodies and anti-cyclic citrullinated peptides antibodies in rheumatoid arthritis].
Galati S; Beauvillain C; Renier G; Jeannin P; Masson C; Chevailler A
Ann Biol Clin (Paris); 2008; 66(2):157-64. PubMed ID: 18390426
[TBL] [Abstract][Full Text] [Related]
37. Clinical utility of the anti-CCP assay in patients with rheumatic diseases.
Lee DM; Schur PH
Ann Rheum Dis; 2003 Sep; 62(9):870-4. PubMed ID: 12922961
[TBL] [Abstract][Full Text] [Related]
38. Rheumatic Disease Autoantibodies in Autoimmune Liver Diseases.
Utiyama SR; Zenatti KB; Nóbrega HA; Soares JZ; Skare TL; Matsubara C; Muzzilo DA; Nisihara RM
Immunol Invest; 2016 Aug; 45(6):566-73. PubMed ID: 27409579
[TBL] [Abstract][Full Text] [Related]
39. Association of circulating antibodies against double-stranded and single-stranded DNA with thyroid autoantibodies in Graves' disease and Hashimoto's thyroiditis patients.
Pedro AB; Romaldini JH; Americo C; Takei K
Exp Clin Endocrinol Diabetes; 2006 Jan; 114(1):35-8. PubMed ID: 16450315
[TBL] [Abstract][Full Text] [Related]
40. HIGH PREVALENCE OF HYPOTHYROIDISM IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITHOUT AN INCREASE IN CIRCULATING ANTI-THYROID ANTIBODIES.
Domingues SL; Gonçalves FT; Jorge MLMP; Limongi JE; Ranza R; Jorge PT
Endocr Pract; 2017 Nov; 23(11):1304-1310. PubMed ID: 28816533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
